Intrasense SA (ALINS) AI Stock Analysis

• Market Cap: €15.02M
• Dividend Yield: N/A
• Average Volume (3M): 40.06K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.33
• Revenue Growth: 13.56%
• EPS Growth: -65.50%
• Country: FR
• Employees: 76
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.05
• Shares Outstanding: 52,716,263
• 10 Day Avg. Volume: 49,808
• 30 Day Avg. Volume: 40,061
• PEG Ratio: -0.04
• Price to Book (P/B): 7.33
• Price to Sales (P/S): 5.40
• P/FCF Ratio: -2.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €0.50
• Price Target Upside: 78.57% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: €0.50 ▲(78.57% Upside)

The overall stock score is primarily impacted by the company's poor financial performance, characterized by declining revenues and consistent losses. Technical indicators suggest bearish momentum, while valuation metrics highlight the lack of profitability. These factors collectively contribute to a low stock score.

Intrasense SA Business Overview & Revenue Model

Company Description

Intrasense SA designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name worldwide. The company offers Myrian Imaging Layer, a multimodal visualization software platform suite for health industrials; Myrian Studio, a solution for the development of medical imaging applications for innovators, industrial clients, spin-offs, and research labs; and Myrian technologies to develop biomarkers and artificial intelligence solutions. It also provides Myrian Clinical Apps, a portfolio of clinical applications for advanced post-processing, which include Myrian XP-Breast; Myrian XP-Prostate; Myrian XP-Liver; Myrian XP-Mammo; Myrian XP-Lung; Myrian XP-Colon; Myrian XL-Onco, a lesion tracking solutions; Myrian XP-Vessel; Myrian XP-Cardiac; solution for pathology or organ; and various tools for the analysis of MRI, CT, conventional, radiology, and nuclear imaging exams. The company was incorporated in 2004 and is headquartered in Montpellier, France.

How the Company Makes Money

Intrasense generates revenue primarily through the sale of its software solutions and services to healthcare institutions, such as hospitals and clinics. The company adopts a subscription-based model for its software, allowing clients to access updates and support over time. Additionally, Intrasense may earn revenue from licensing agreements, training services for healthcare professionals, and potential partnerships with medical device manufacturers or healthcare IT companies. These partnerships can enhance its product offerings and market reach, contributing to stable revenue growth.

Intrasense SA Financial Statement Overview

Summary

Intrasense SA is experiencing declining revenues, consistent losses, and a weak balance sheet. Negative margins and cash flow indicate operational inefficiencies and financial instability. The high leverage and low equity position further accentuate financial risk.

Income Statement

Intrasense SA has been experiencing declining revenue with a negative trend in profitability. The gross profit margin is negative, indicating cost of goods sold exceeds revenue. Net profit margin is also negative, reflecting consistent net losses. There is a concerning decline in revenue over the years, with significant operating losses as evidenced by negative EBIT and EBITDA margins.

Balance Sheet

The company's balance sheet shows a high debt-to-equity ratio, indicating reliance on debt financing. The equity ratio is low, reflecting potential financial instability. Return on equity is negative, indicating that shareholders are not seeing returns on their investment. These factors suggest financial vulnerability and limited equity to cover liabilities.

Cash Flow

Intrasense SA reports negative operating cash flow and free cash flow, highlighting cash burn and operational challenges. The company is not generating sufficient cash from operations to cover expenses, and free cash flow is declining, indicating worsening cash position over time. The operating cash flow to net income ratio is negative, suggesting poor cash earnings quality.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.65M	2.25M	3.31M	3.79M	4.19M	3.44M
Gross Profit	-6.07M	-3.81M	-885.00K	-1.15M	-1.05M	-454.00K
EBITDA	-5.37M	-4.60M	-2.68M	-2.09M	-611.00K	-30.00K
Net Income	-6.48M	-5.66M	-3.58M	-3.42M	-1.20M	-704.00K
Balance Sheet
Total Assets	9.19M	7.68M	10.45M	6.51M	8.77M	6.36M
Cash, Cash Equivalents and Short-Term Investments	1.44M	930.00K	4.55M	1.41M	4.76M	2.59M
Total Debt	1.37M	1.41M	1.49M	2.06M	1.93M	2.26M
Total Liabilities	10.36M	6.03M	3.17M	4.50M	3.78M	4.21M
Stockholders Equity	-1.16M	1.65M	7.29M	2.01M	4.99M	2.15M
Cash Flow
Free Cash Flow	-6.50M	-5.94M	-4.97M	-3.48M	-1.50M	-1.08M
Operating Cash Flow	-4.62M	-3.73M	-3.05M	-2.00M	-948.00K	-481.00K
Investing Cash Flow	-1.86M	-2.21M	-1.93M	-1.49M	-555.00K	-551.00K
Financing Cash Flow	6.61M	2.33M	8.10M	98.00K	3.62M	2.71M

Intrasense SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALINS, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.29, below the 50-day MA of 0.29, and below the 200-day MA of 0.28, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.94 is Neutral, neither overbought nor oversold. The STOCH value of 4.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALINS.

Intrasense SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALAMA	48 Neutral	€14.82M	―	―	―	-17.36%	8.61%
ALMDT	44 Neutral	€113.04M	―	―	―	3.25%	-2.07%
ALINS	41 Neutral	€15.02M	―	-314.39%	―	13.56%	-65.50%